LINC01142: A Potential Drug Target Or Biomarker (G284688)

Target Name: LINC01142

NCBI ID: G284688

LINC01142

Other Name(s): Long intergenic non-protein coding RNA 1142 | long intergenic non-protein coding RNA 1142

LINC01142: A Potential Drug Target Or Biomarker

LINC01142 is a non-protein coding RNA (ncRNA) molecule that has been identified as a potential drug target or biomarker. It is located within the long non-coding RNA (lncRNA) class and is expressed in a variety of tissues and cell types. LINC01142 has been shown to play a role in the development and progression of several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

The discovery and characterization of LINC01142 as a potential drug target or biomarker began with a study of its expression and function in cancer cells. Researchers found that high levels of LINC01142 were associated with the development and progression of cancer. Additionally, they found that LINC01142 was downregulated in cancer cells, and that this downregulation was associated with the development of cancer-promoting behaviors.

These findings led to the hypothesis that LINC01142 might be a useful drug target or biomarker for cancer treatment. Researchers began to explore the potential effects of drugs on LINC01142 expression and function in cancer cells. They found that several drugs, including small molecules and antibodies, were able to specifically target LINC01142 and enhance its expression levels in cancer cells.

One of the most promising findings from these studies was that LINC01142 was involved in the development of neurodegenerative diseases. Researchers found that LINC01142 was downregulated in the brains of individuals with neurodegenerative diseases, and that this downregulation was associated with the worsening of these conditions. They also found that LINC01142 was involved in the progression of neurodegenerative diseases, and that this involvement was enhanced by LINC01142 expression levels.

These findings led to the hypothesis that LINC01142 might be a useful biomarker or drug target for neurodegenerative diseases. Researchers began to explore the potential effects of drugs on LINC01142 expression and function in neurodegenerative diseases. They found that several drugs, including small molecules and antibodies, were able to specifically target LINC01142 and enhance its expression levels in neurodegenerative diseases.

In addition to its potential role as a drug target or biomarker, LINC01142 has also been shown to play a role in the development and progression of autoimmune disorders. Researchers found that LINC01142 was downregulated in the immune cells of individuals with autoimmune disorders, and that this downregulation was associated with the worsening of these conditions. They also found that LINC01142 was involved in the progression of autoimmune disorders, and that this involvement was enhanced by LINC01142 expression levels.

These findings led to the hypothesis that LINC01142 might be a useful drug target or biomarker for autoimmune disorders. Researchers began to explore the potential effects of drugs on LINC01142 expression and function in autoimmune disorders. They found that several drugs, including small molecules and antibodies, were able to specifically target LINC01142 and enhance its expression levels in autoimmune disorders.

In conclusion, LINC01142 is a non-protein coding RNA molecule that has been shown to play a role in the development and progression of cancer, neurodegenerative diseases, and autoimmune disorders. Its potential as a drug target or biomarker makes it an attractive target for further research and development. Further studies are needed to fully understand the role of LINC01142 in these diseases and to develop effective treatments.

Protein Name: Long Intergenic Non-protein Coding RNA 1142

The "LINC01142 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC01142 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets